By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has commenced its tender offer to acquire Celera for $8 per share.

The offer is being made through Quest's wholly owned subsidiary, Spark Acquisition Corp., and will expire on April 25 at 5:00 pm New York City time. The offer is subject to customary conditions, including the tender of a majority of Celera's outstanding shares and certain regulatory approvals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.